{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:02:54Z","timestamp":1771275774560,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","award":["IT-72-RG-33\/ISR004983"],"award-info":[{"award-number":["IT-72-RG-33\/ISR004983"]}],"id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007705","name":"Astellas | Astellas Pharma Global Development","doi-asserted-by":"publisher","award":["IT-72-RG-33\/ISR004983"],"award-info":[{"award-number":["IT-72-RG-33\/ISR004983"]}],"id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41391-025-00975-8","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:07:07Z","timestamp":1746270427000},"page":"116-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-7663","authenticated-orcid":false,"given":"Alberto","family":"Dalla Volta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Valcamonico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Zivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierangela","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0481-953X","authenticated-orcid":false,"given":"Gianluca","family":"Del Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunzia","family":"Di Meo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Foti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ravanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Calza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7448-7822","authenticated-orcid":false,"given":"Francesca","family":"Zacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovannino","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4331-3010","authenticated-orcid":false,"given":"Nazareno","family":"Suardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5664-353X","authenticated-orcid":false,"given":"Roberto","family":"Maroldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"975_CR1","doi-asserted-by":"publisher","first-page":"100575","DOI":"10.1016\/j.esmoop.2022.100575","volume":"7","author":"BA Maiorano","year":"2022","unstructured":"Maiorano BA, De Giorgi U, Roviello G, Messina C, Altavilla A, Cattrini C, et al. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. ESMO Open. 2022;7:100575. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100575.","journal-title":"ESMO Open"},{"key":"975_CR2","doi-asserted-by":"publisher","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40:1616\u201322. https:\/\/doi.org\/10.1200\/JCO.22.00193.","DOI":"10.1200\/JCO.22.00193"},{"key":"975_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835.","journal-title":"N Engl J Med"},{"key":"975_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2009.0076","volume":"7","author":"JR Gralow","year":"2009","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw. 2009;7:S1\u201332. https:\/\/doi.org\/10.6004\/jnccn.2009.0076.","journal-title":"J Natl Compr Canc Netw"},{"key":"975_CR5","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1200\/JCO.2010.34.4994","volume":"29","author":"PJ Saylor","year":"2011","unstructured":"Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011;29:3705\u201314. https:\/\/doi.org\/10.1200\/JCO.2010.34.4994.","journal-title":"J Clin Oncol"},{"key":"975_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07568-9","volume":"20","author":"L Wang","year":"2020","unstructured":"Wang L, Fang D, Xu J, Luo R. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020;20:1059. https:\/\/doi.org\/10.1186\/s12885-020-07568-9.","journal-title":"BMC Cancer"},{"key":"975_CR7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458\u201368. https:\/\/doi.org\/10.1093\/jnci\/94.19.1458.","journal-title":"J Natl Cancer Inst"},{"key":"975_CR8","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","volume":"32","author":"MR Smith","year":"2014","unstructured":"Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014;32:1143\u201350. https:\/\/doi.org\/10.1200\/JCO.2013.51.6500.","journal-title":"J Clin Oncol"},{"key":"975_CR9","doi-asserted-by":"publisher","first-page":"S954","DOI":"10.1016\/annonc\/annonc1334","volume":"34","author":"C Jones","year":"2023","unstructured":"Jones C, Dutey-Magni P, Murphy LR, Murray M, Brown JE, McCloskey E, et al. Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: Analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons. Ann Oncol. 2023;34:S954\u20131000. https:\/\/doi.org\/10.1016\/annonc\/annonc1334.","journal-title":"Ann Oncol"},{"key":"975_CR10","doi-asserted-by":"publisher","first-page":"E1147","DOI":"10.1111\/j.1464-410X.2012.11392.x","volume":"110","author":"Y Cirak","year":"2012","unstructured":"Cirak Y, Varol U, Atmaca H, Kisim A, Sezgin C, Karabulut B, et al. Zoledronic acid in combination with serine\/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. BJU Int. 2012;110:E1147\u201354. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11392.x.","journal-title":"BJU Int"},{"key":"975_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s13277-014-2682-6","volume":"36","author":"U Varol","year":"2015","unstructured":"Varol U, Degirmenci M, Karaca B, Atmaca H, Kisim A, Uzunoglu S, et al. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines. Tumour Biol. 2015;36:779\u201386. https:\/\/doi.org\/10.1007\/s13277-014-2682-6.","journal-title":"Tumour Biol"},{"key":"975_CR12","doi-asserted-by":"publisher","first-page":"7675","DOI":"10.1007\/s11033-020-05840-6","volume":"47","author":"C Gokalp","year":"2020","unstructured":"Gokalp C. Cytotoxic and anti-angiogenic effects of zoledronic acid in DU-145 and PC-3 prostate cancer cell lines. Mol Biol Rep. 2020;47:7675\u201383. https:\/\/doi.org\/10.1007\/s11033-020-05840-6.","journal-title":"Mol Biol Rep"},{"key":"975_CR13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2015.04.032","volume":"68","author":"F Saad","year":"2015","unstructured":"Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, et al. Impact of bone-targeted therapies in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015;68:570\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.032.","journal-title":"Eur Urol"},{"key":"975_CR14","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.2214\/AJR.11.8351","volume":"199","author":"F Mosavi","year":"2012","unstructured":"Mosavi F, Johansson S, Sandberg DT, Turesson I, S\u00f6rensen J, Ahlstr\u00f6m H. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET\/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol. 2012;199:1114\u201320. https:\/\/doi.org\/10.2214\/AJR.11.8351.","journal-title":"AJR Am J Roentgenol"},{"key":"975_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/jmri.24548","volume":"39","author":"AR Padhani","year":"2014","unstructured":"Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, de Bono JS. Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging. 2014;39:1049\u201378. https:\/\/doi.org\/10.1002\/jmri.24548.","journal-title":"J Magn Reson Imaging"},{"key":"975_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, et al. METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol. 2017;71:81\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.033.","journal-title":"Eur Urol"},{"key":"975_CR17","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Prostate cancer clinical trials working group 3. trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"975_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","volume":"68","author":"B Tombal","year":"2015","unstructured":"Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Long-term efficacy and safety of enzalutamide monotherapy in hormone-na\u00efve prostate cancer: 1- and 2-year open-label follow-up results. Eur Urol. 2015;68:787\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2015.01.027.","journal-title":"Eur Urol"},{"key":"975_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.4780030106","volume":"3","author":"R Simon","year":"1984","unstructured":"Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3:35\u201344. https:\/\/doi.org\/10.1002\/sim.4780030106.","journal-title":"Stat Med"},{"key":"975_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17:243\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(15)00489-1. FebEpub 2015 Dec 21. Erratum in: Lancet Oncol. 2016 Feb;17(2):e46. 10.1016\/S1470-2045(16)00020-6.","journal-title":"Lancet Oncol"},{"key":"975_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.772530","volume":"11","author":"Oprea-Lager DE","year":"2021","unstructured":"Oprea-Lager DE, Cysouw MCF, Boellaard R, Deroose CM, de Geus-Oei LF, Lopci E, et al. Bone metastases are measurable: the role of whole-body MRI and positron emission tomography. Front Oncol. 2021;11:772530. https:\/\/doi.org\/10.3389\/fonc.2021.772530.","journal-title":"Front Oncol"},{"key":"975_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.eururo.2024.02.016","volume":"86","author":"A Garcia-Ruiz","year":"2024","unstructured":"Garcia-Ruiz A, Macarro C, Zacchi F, Morales-Barrera R, Grussu F, Casanova-Salas I, et al. Whole-body magnetic resonance imaging as a treatment response biomarker in castration-resistant prostate cancer with bone metastases: the iPROMET clinical trial. Eur Urol. 2024;86:272\u20134. https:\/\/doi.org\/10.1016\/j.eururo.2024.02.016.","journal-title":"Eur Urol"},{"key":"975_CR23","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974\u201386. https:\/\/doi.org\/10.1200\/JCO.19.00799.","journal-title":"J Clin Oncol"},{"key":"975_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.eururo.2024.05.004","volume":"86","author":"A Dalla Volta","year":"2024","unstructured":"Dalla Volta A, Valcamonico F, Zivi A, Procopio G, Sepe P, Del Conte G, et al. Whole-body diffusion-weighted magnetic resonance imaging for assessment of the bone response rate in patients with metastatic hormone-sensitive prostate cancer receiving enzalutamide. Eur Urol. 2024;86:268\u201371. https:\/\/doi.org\/10.1016\/j.eururo.2024.05.004.","journal-title":"Eur Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00975-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00975-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00975-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:04:43Z","timestamp":1771272283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00975-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00975-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"17 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}